O. Lingjaerde et al., A DOUBLE-BLIND COMPARISON OF MOCLOBEMIDE AND DOXEPIN IN DEPRESSED GENERAL-PRACTICE PATIENTS, Acta psychiatrica Scandinavica, 92(2), 1995, pp. 125-131
A total of 56 patients attending a general practitioner for treatment
of depression, most of whom met the criteria for major depression, wer
e included in this double-blind, parallel group, 6-week study, in whic
h the selective MAO-A inhibitor moclobemide (MOC; maximum dose 600 mg)
was compared with the tricyclic antidepressant doxepin (DOX; maximum
dose 250 mg). Thirty patients on MOC and 23 on DOX were assessed after
treatment for at least 1 week and are included in the response evalua
tion. Improvement was assessed primarily with the Montgomery-Asberg De
pression Rating Scale (MADRS). There were only 4 drop-outs in the MOC
group and three in the DOX group after 1 week. Overall improvement mea
sures showed a nonsignificant difference in favor of DOX. Two factors
were found to have prognostic significance: (1) previous or present pa
nic attacks (10 patients in the MOC group and - by chance - only one i
n the DOX group) were associated with significantly lower improvement
within the MOC group. Since we had no a priori hypothesis about this e
ffect, it could be a chance finding. (2) Improvement was negatively co
rrelated with age; this was statistically significant in the total gro
up as well as in the MOC group, with a nonsignificant trend in the sam
e direction in the DOX group. Side effects differed little between the
two groups; only dryness of mouth appeared with markedly higher frequ
ency in the DOX group.